An overview of fumarates available as treatment for relapsing multiple sclerosis and recommendations for counseling and caring for patients on these therapies.
Anti-CD20 Utilization in Relapsing MS
Considerations for using anti-CD20 therapies versus other available treatment options for relapsing multiple sclerosis.
Omavelexolone’s Potential in Friedreich Ataxia: David R. Lynch, MD, PhD
September 24th 2021The professor of neurology at the University of Pennsylvania Perelman School of Medicine discussed his presentation at MDS 2021, which highlighted the therapeutic benefit of omaveloxolone in Friedreich ataxia. [WATCH TIME: 2 minutes]
Ongoing Therapeutic Developments for Movement Disorders: Saar Anis, MD
September 23rd 2021When asked about developments, the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center in Israel commented on the need to identify disease-modifying therapies. [WATCH TIME: 3 minutes]
Understanding the Use of Medical Cannabis for Movement Disorders: Saar Anis, MD
September 22nd 2021Following his presentation at the MDS Society Virtual Congress 2021, the neurologist and movement disorders specialist at Sheba Tel-HaShomer Medical Center discussed his views on the use of medical cannabis. [WATCH TIME: 3 minutes]
Future Direction of AI, Neuroimaging Research: Michael Dwyer, PhD
September 22nd 2021The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center discussed future neuroimaging projects the center is evaluating and where the focus turns to next. [WATCH TIME: 3 minutes]
Studying Effects of Gender and Sex in Alzheimer Disease: Jessica Caldwell, PhD
September 21st 2021The director of The Women’s Alzheimer’s Movement Prevention Center at Cleveland Clinic discussed her recently awarded NIH grant and her work to understand why women are more likely to be impacted by Alzheimer disease.
Anti-CD20 Therapies for Relapsing MS
An overview of clinical trial data supporting the use of ocrelizumab and ofatumumab as treatment options for patients with relapsing multiple sclerosis.
Selecting an S1P Modulator for Relapsing MS
Variables that impact which S1P receptor modulator is selected as treatment for relapsing multiple sclerosis.
Efficacy, Safety, and Tolerability of Apomorphine Sublingual Film: William Ondo, MD
September 17th 2021The director of the Movements Disorders Clinic at Houston Methodist Neurological Institute discussed data presented at the International Parkinson and Movement Disorders Society Virtual Congress 2021.
How APPs and Organizations Can Address the Neurologist Shortage: Jennifer Majersik, MD, MS
September 16th 2021The director of the division of vascular neurology at the University of Utah discussed ongoing efforts from the AAN, as well as the potential to integrate advanced practice providers into neurology teams.
Applying Artificial Intelligence and Neuroimaging Into Clinical Care: Michael Dwyer, PhD
September 16th 2021The director of IT and Neuroinformatics Development at the Buffalo Neuroimaging Analysis Center provided a realistic perspective of when and how AI will be incorporated into the wider medical system.
The Critical Nature of Patient-Focused MS Care: Patricia Bobryk, MHS, PT, MSCS, ATP
September 15th 2021With the field of multiple sclerosis care focusing on the importance of patient-reported outcomes and shared decision-making, the physical therapist at UC Health and cochair of the International Organization of MS Rehabilitation Therapists offered commentary.
The Availability of MS Rehabilitation Therapists: Patricia Bobryk, MHS, PT, MSCS, ATP
September 13th 2021Amid an ongoing national shortage of clinicians who treat neurologic diseases like MS, the cochair of the International Organization of MS Rehabilitation Therapists discussed the availability of rehabilitation professionals for patients.
Early Intervention With Physical Therapy for MS: Patricia Bobryk, MHS, PT, MSCS, ATP
September 12th 2021The physical therapist at UC Health and cochair of the International Organization of MS Rehabilitation Therapists spoke to the current standards of rehabilitative care among patients with multiple sclerosis.